Nov 15, 2021 / 08:20PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks, everybody, for continuing to join on. It's my pleasure to be hosting a discussion with Barry Greene, CEO of Sage, who I and probably everyone listening have known for a long time since his Alnylam days. Barry, thanks again. Maybe you want to just do the sort of obligatory 3- to 4-minute kick off and give an update on zuranolone, SAGE-324, SAGE-718 and then we can get into more specifics.
Barry E. Greene - Sage Therapeutics, Inc. - President, CEO & Director
Yes, absolutely, Paul. Thanks, and I'd like to thank Stifel for having us here today. As we set out in January and established the goals for this year, we have executed on the expand and accelerate strategy we set out. We've seen, as you know, positive readouts for zuranolone, SAGE-324 and SAGE-718. It's quite remarkable. And we've gotten clarity with the agency for our filing path along with filing path for zuranolone in the second half of 2022 with the
SAGE Therapeutics Inc at Stifel Healthcare Conference (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers